

## REVIEW ARTICLE

# Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis

M. Alonso-Moreno\*, M. Ladrón-Guevara, P. Ciudad-Gutiérrez

Pharmacy Service, Hospital Universitario Virgen del Rocío, Avenue Manuel Siurot, 41013 Seville, Spain

Received 21 October 2020; accepted 1 January 2021

## KEYWORDS

Gender;  
Sex;  
Ocrelizumab;  
Natalizumab;  
Alemtuzumab;  
Rituximab

## Abstract

**Introduction:** This article analyses the presence of gender bias in clinical trials of monoclonal antibodies used to treat multiple sclerosis.

**Material and methods:** We performed a systematic review of controlled clinical trials of 4 monoclonal antibodies used to treat multiple sclerosis (natalizumab, rituximab, alemtuzumab, and ocrelizumab). We searched the PubMed/MEDLINE database for articles published in English before March 2020. The study was conducted in accordance with the relevant international recommendations.

**Results:** The search identified 89 articles, 55 of which met the inclusion criteria. Of all patients included in these trials, 64.6% were women. The lead authors of 10 of the studies were women. Fifteen of the 55 studies included a sex-based analysis of the primary endpoint. Only 8 articles discussed the results separately for men and for women.

**Conclusions:** The clinical trials of these 4 monoclonal antibodies present a significant gender bias. In most cases, the primary and secondary endpoints are not analyzed according to patient sex, despite the fact that international recommendations include this as a minimum requirement for ensuring scientific validity and obtaining appropriate results for extrapolation to the wider population.

© 2021 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [martalonsomoren@gmail.com](mailto:martalonsomoren@gmail.com) (M. Alonso-Moreno).

**PALABRAS CLAVE**

Género;  
Sexo;  
Ocrelizumab;  
Natalizumab;  
Alemtuzumab;  
Rituximab

**Revisión sistemática sobre el sesgo de género en los ensayos clínicos de anticuerpos monoclonales para el tratamiento de la esclerosis múltiple****Resumen**

**Introducción:** Este artículo evalúa el sesgo de género presente en los ensayos clínicos sobre anticuerpos monoclonales para el tratamiento de la esclerosis múltiple.

**Materiales y métodos:** Se realizó una revisión sistemática de ensayos clínicos controlados de 4 anticuerpos monoclonales (natalizumab, rituximab, alemtuzumab y ocrelizumab) para el tratamiento de la esclerosis múltiple a través de las bases de datos Pubmed/Medline, publicados hasta marzo de 2020 y los cuales fueron escritos en inglés. El estudio siguió las correspondientes recomendaciones internacionales.

**Resultados:** Se identificaron 89 artículos, de los cuales 55 cumplieron los criterios de inclusión. Se encontró que el 64,6% del total de pacientes eran mujeres. El sexo del primer autor era femenino en 10 ensayos clínicos. El análisis de la variable principal en función del sexo se realizó en 15 de los 55 artículos incluidos. Además, solo 8 ensayos clínicos discutieron los resultados separadamente de acuerdo al sexo.

**Conclusiones:** Los ensayos clínicos de estos 4 anticuerpos monoclonales muestran un sesgo de género significativo. En su mayoría, la variable principal y secundarias no son analizadas en función del sexo. Esto se produce a pesar de las recomendaciones internacionales que lo establecen, como requisito mínimo, para dar validez científica y obtener unos resultados apropiados para extender su aplicación a la población global.

© 2021 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Neurología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

Multiple sclerosis (MS) is 2 to 3 times more frequent in women than in men.<sup>1</sup> In the last decades, some studies have revealed that the incidence of MS in women may be increasing, being more significant in countries located in Northern latitudes.<sup>2,3</sup> The reasons for this increase remain unknown, but some authors suggest that they could be influenced by environmental or immunological factors.<sup>4,5</sup>

On the other hand, the average age at which the first symptoms of MS appear, usually ranges between the second and the third decade of life in the general population,<sup>1</sup> but those symptoms present even earlier in women than in men.<sup>3</sup>

Likewise, men experience a faster progression of the disease and a worse prognosis, with greater cognitive disorders and brain atrophy. However, women suffer a greater number of flares, with more inflammatory lesions that are shown on nuclear magnetic resonance imaging.<sup>3</sup>

Currently, the biological treatment with monoclonal antibodies is considered one of the most effective therapies in reducing inflammation and in the number of flares in MS patients. Furthermore, various authors advise "personalizing" this type of therapy by monitoring adverse effects and developing individual strategies to detect possible treatment failures.<sup>6</sup> However, there is little evidence on the study of the efficacy and safety of the drugs used in MS based on gender,<sup>7</sup> being this analysis particularly interesting to individualize patients' treatments.

The National Institute of Health requires the inclusion of women in phase III clinical trials to ensure adequate analysis of data based on sex.<sup>8</sup> These recommendations served as the basis for the preparation of the SAGER guidelines, a

tool used to systematize data based on gender and type in scientific publications, when required.<sup>9</sup> In 1993, "The Food and Drug Administration" (FDA) published a guide that also promotes the participation of women in clinical trials (CT)<sup>10</sup> and that was not replicated in Europe.<sup>11</sup> Finally, some similar initiatives have emerged from other organizations such as: "The International Committee of Medical Journal Editors"<sup>12</sup> or "The Canadian Institute of Health",<sup>13</sup> which highlight the significance of promoting the perspective of gender and sex in the research and scientific articles.

Some systematic reviews have shown gender bias in different medical specialties in the design of CT. For example, a low female representation in CT has been verified with antiretroviral drugs<sup>14</sup> or with long-acting antipsychotic drugs,<sup>15</sup> and even in certain studies that treat different types of cancer that are not gender-specific.<sup>16</sup> Finally, according to a review of randomized clinical trials published in high impact journals, an over-representation of men has been found in 43% of the studies without explicit exclusion of women in the selection process.<sup>17</sup>

The goal of this study was to assess if the published CTs on monoclonal antibodies authorized in the treatment of MS, followed the international recommendations to avoid gender bias.

**Methods**

CTs of monoclonal antibodies used in the treatment of Multiple Sclerosis (Ocrelizumab, Rituximab, Alemtuzumab and Natalizumab) were collected through the PubMed/MEDLINE database published in English until March 2020. Only

**Table 1** Research strategy PubMed/MEDLINE.

("natalizumab" AND "multiple sclerosis") AND  
 ("rituximab" AND "multiple sclerosis") AND  
 ("ocrelizumab" AND "multiple sclerosis") AND  
 ("alemtuzumab" AND "multiple sclerosis")

**Table 2** Inclusion and exclusion criteria.**Inclusion criteria**

The study drug had to be natalizumab, rituximab, ocrelizumab or alemtuzumab.

The CT had to have a control group and use random allocation.

The treated patients had to be over 18 years of age.

The diagnosis of the CT participants had to be Multiple Sclerosis.

**Exclusion criteria**

Pilot studies with a small sample of patients.

Reviews and meta-analyses.

Short reports, letters to the editor, expert opinions or clinical notes.

monoclonal antibodies were selected in this study because they are the newest therapies in EM. Daclizumab and Opicinumab were excluded because they have not been approved by European Medicine Agency (EMA).

To obtain the full text of the articles that did not have this modality in the journal itself, they used the Virtual Library of the Public Health System of Andalusia.

The literature search strategy can be seen in [Table 1](#).

The following filter was used: Clinical Trials.

The inclusion and exclusion criteria can be seen in [Table 2](#).

The following study characteristics were recorded:

- Drug under study: ocrelizumab, alemtuzumab, rituximab o natalizumab.
- Publication year: divided into CT published from 2000 to 2009, and from 2010 to 2019.
- Location of the trial: international or other (United States, Japan, ...). the post hoc studies identified the CT they were coming from.
- CT phase: I, II, III or IV. In those CT where phase II/III were considered phase III.
- Something used as a standard for comparison: placebo or active drug (in multiarm trials, whenever one of them was active drug, the comparator was considered active drug).
- Type of CT according to its main outcomes: efficacy and/or safety, PK/PD.
- Financing of the CT: pharmaceutical industry or independent (trials were considered to be promoted by the pharmaceutical industry if one of the authors was employed by a pharmaceutical company).
- Main diagnosis: progressive primary MS (PPMS), progressive secondary MS (PSMS), recurring remittent MS (RRMS) and progressive remittent MS (PRMS).
- Total number of participants.
- Author gender.
- If studies described pregnancy as an exclusion criterion.

- If they discussed the results analyzed based on gender.
- If there was an analysis of the interaction between hormone replacement therapy AND study drug, included women using hormonal contraceptives.
- If there was a study of the influence of the phase of the menstrual cycle on the pharmacokinetics and response to the drug.

The following main variables were analyzed: percentage of women among the total number of patients recruited and percentage of CT presenting the main results arranged by sex.

The percentage of women was estimated with the raw data (number of women among the total number of patients in each subgroup). Post hoc studies were not taken into account for the total number of patients or the number and percentage of women since they used the same population of the CT they came from. However, it was analyzed if the post hoc study included an analysis based on gender of the main variable or other variables that was not included in the analysis of the first publication of the original trial.

For the analysis of gender differences, they used the SAGER guidelines<sup>9</sup> and the FDA guide<sup>11</sup> mentioned above. The basic statistics of the central tendency were estimated, analyzing the following subgroups: study type, drug, place, drugs used as a standard for comparison, date of publication, CT phase, type of objective, sample size, funding and first author sex.

This systematic review was performed in accordance with the PRISMA-E 2012 guide.<sup>18</sup>

## Results

A total of 89 studies were identified in the literature search; of these, 55 complied with the inclusion and exclusion criteria ([Fig. 1](#)).

[Table 3](#) shows the characteristics of the trials included in the study.

[Table 4](#) shows the proportion of women and the evaluation of the results based on sex in the different subgroups of the CTs.

Most of the studies were done with natalizumab, followed by alemtuzumab, ocrelizumab and rituximab. 6 trials had less than 100 patients, 18 between 101 and 500, 14 between 501 and 1000, and 17 studies had more than 1001 patients. Seventeen trials were published between 2000 and 2009 and 38 between 2010 and 2019. 92.73% of the trials were carried out worldwide. 14 trials were performed in phase II, 38 in phase III and 3 in phase IV. Something used as a standard for comparison was placebo in 25 trials and another active drug in the remaining studies. The trials measured the variables of efficacy and safety,<sup>30</sup> efficacy,<sup>20</sup> safety,<sup>3</sup> PKPD parameters.<sup>2</sup>

Most of the studies (48/55) were financed by pharmaceutical companies. Moreover, in most of them (40/55) the main diagnosis was RRMS, in 3 studies it was RRMS, in 2 it was PRMS, in 1, it was PSMS and in 9 studies they included more than one type of MS. There were no clear differences between the studies that included one or more typologies related to the main variables.

**Table 3** Features of the included clinical trials.

study	Drug	CT Localization <sup>a</sup>	CT phase	Comparator <sup>b</sup>	Type of CT	Financed by industry?	First/ corresponding author sex	Women/ Total patients <sup>c</sup>	Women percentages <sup>c</sup>
Coles et al., 2008 (CAMMS23II study) <sup>19</sup>	Alemtuzumab	International	II	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	214/334	64 .1%
Coles et al., 2011 <sup>20</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	II	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Cukier et al., 2011 <sup>21</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	II	Interferon-beta-1a	Safety	Yes, employees	Male	—	—
Cohen et al., 2012 (CARE-MS I study) <sup>22</sup>	Alemtuzumab	International	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	365/563	64 .8%
Coles et al., 2012 <sup>23</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Coles et al., 2012 (CARE-MS II study) <sup>24</sup>	Alemtuzumab	International	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	532/798	66 .7%
Graves et al., 2013 <sup>25</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	II	Interferon-beta-1a	Efficacy	Yes, employees	Female	—	—
Daniels et al., 2014 <sup>26</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	II	Interferon-beta-1a	Safety	Yes, employees	Male	—	—
Arnold et al., 2016 <sup>27</sup>	Alemtuzumab	Post hoc analysis of CARE-MS I (Cohen et al., 2012) and CARE-MS II (Coles et al., 2012) studies	III	Interferon-beta-1a	Efficacy	—	Male	—	—
Fox et al., 2016 <sup>28</sup>	Alemtuzumab	Post hoc analysis of CAMMS23II study (Coles et al., 2008)	II	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Giovannoni et al., 2016 <sup>29</sup>	Alemtuzumab	Post hoc analysis of CARE-MS II study (Coles et al., 2012)	III	Interferon-beta-1a	Efficacy	Yes, employees	Male	—	—
Arroyo et al., 2017 <sup>30</sup>	Alemtuzumab	Post hoc analysis of CARE-MS I (Cohen et al., 2012) and CARE-MS II (Coles et al., 2012) studies	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Havrdova et al., 2017 <sup>31</sup>	Alemtuzumab	Post hoc analysis of CARE-MS I study (Cohen et al., 2012)	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Li et al., 2018 <sup>32</sup>	Alemtuzumab	Post hoc analysis of CARE-MS I (Cohen et al., 2012), CARE-MS II (Coles et al., 2012) and CAMMS23II studies (Coles et al., 2008)	II/III	Interferon-beta-1a	PK/PD <sup>c</sup>	Yes, employees	Male	—	—
Miller et al., 2003 <sup>33</sup>	Natalizumab	International	II	Placebo	Efficacy/Safety	No	Male	152/213	71 .4%
Dalton et al., 2004 <sup>34</sup>	Natalizumab	International	III	Placebo	Efficacy	Yes, employees	Female	53/78	67 .9%
O'Connor et al., 2004 <sup>35</sup>	Natalizumab	International	II	Placebo	Efficacy/Safety	No	Male	33/180	18 .3%
O'Connor et al., 2005 <sup>36</sup>	Natalizumab	Post hoc analysis (Miller et al., 2003)	II	Placebo	Efficacy	No	Male	—	—

Table 3 (Continued)

Study	Drug	CT Localization <sup>a</sup>	CT phase	Comparator <sup>b</sup>	Type of CT	Financed by industry?	First/ corresponding author sex	Women/ Total patients <sup>c</sup>	Women percentages <sup>c</sup>
Polman et al., 2006 (AFFIRM study) <sup>37</sup>	Natalizumab	International	III	Placebo	Efficacy/Safety	Yes, employees	Male	660/942	70 .1%
Rudick et al., 2006 (SENTINEL study) <sup>38</sup>	Natalizumab	International	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	862/1171	73 .7%
Balcer et al., 2007 <sup>39</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Female	—	—
Calabresi et al., 2007 <sup>40</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Soon et al., 2007 <sup>41</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006)	III	Placebo	Efficacy	No	Male	—	—
Miller et al., 2007 <sup>42</sup>	Natalizumab	Post hoc analysis of AFFIRM study (Polman et al., 2006)	III	Placebo	Efficacy/Safety	Yes, employees	Male	—	—
Rudick et al., 2007 <sup>43</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Goodman et al., 2009 <sup>44</sup>	Natalizumab	International	II	Glatiramer	Efficacy/Safety	Yes, employees	Male	84/110	76 .4%
Havrdova et al., 2009 <sup>45</sup>	Natalizumab	Post hoc analysis of AFFIRM study (Polman et al., 2006)	III	Placebo	Efficacy/Safety	Yes, employees	Female	—	—
Hutchinson et al., 2009 <sup>46</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Radue et al., 2010 <sup>47</sup>	Natalizumab	Post hoc analysis of SENTINEL (Rudick et al., 2006) study	III	Interferon-beta-1a	Efficacy/Safety	No	Male	—	—
Bates et al., 2011 <sup>48</sup>	Natalizumab	Post hoc-analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy	Yes, employees	Male	—	—
Cree et al., 2011 <sup>49</sup>	Natalizumab	Post hoc-analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Placebo	Efficacy	No	Male	—	—
Phillips et al., 2011 <sup>50</sup>	Natalizumab	Post hoc analysis of AFFIRM study (Polman et al., 2006)	III	Placebo	Efficacy	Yes, employees	Male	—	—
Balcer et al., 2012 <sup>51</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) study	III	Placebo	Efficacy/Safety	Yes, employees	Female	—	—
Weinstock-Guttman et al., 2012 <sup>52</sup>	Natalizumab	Post hoc-analysis of AFFIRM (Polman et al., 2006) and SENTINEL (Rudick et al., 2006) studies	III	Interferon-beta-1a	Efficacy	Yes, employees	Female	—	—
Kappos et al., 2013 <sup>53</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and TOP studies	III	Placebo	Efficacy	Yes, employees	Male	—	—
Fox et al., 2014 (RESTORE study) <sup>54</sup>	Natalizumab	International	IV	Interferon-beta-1a, Glatirameracetate or methylprednisolone	Efficacy	Yes, employees	Male	135/175	77 .1%
Kaufman et al., 2014 <sup>55</sup>	Natalizumab	Post hoc analysis of RESTORE study (Fox et al., 2014)	IV	Interferon-beta-1a, Glatirameracetate or methylprednisolone	Efficacy	Yes, employees	Male	—	—
Lublin et al., 2014 <sup>56</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) study	III	Placebo	Efficacy/Safety	Yes, employees	Male	—	—
Chahin et al., 2015 <sup>57</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) study	III	Placebo	Efficacy/Safety	Yes, employees	Male	—	—

Table 3 (Continued)

Study	Drug	CT Localization <sup>a</sup>	CT phase	Comparator <sup>b</sup>	Type of CT	Financed by industry?	First/ corresponding author sex	Women/ Total patients <sup>c</sup>	Women percentages <sup>c</sup>
Kaufman et al., 2015 <sup>58</sup>	Natalizumab	International	IV	Placebo	Efficacy	Yes, employees	Male	51/60	85.0%
Plavina et al., 2017 <sup>59</sup>	Natalizumab	Post hoc analysis of AFFIRM (Polman et al., 2006) and RESTORE (Fox et al., 2014) studies	III	Interferon-beta-1a, Glatirameracetate or methylprednisolone	PK/PD <sup>d</sup>	Yes, employees	Female	—	—
Saida et al., 2017 <sup>60</sup>	Natalizumab	Japanese	II	Placebo	Efficacy/Safety	Yes, employees	Male	73/106	68.9%
Kapoor et al., 2018 <sup>61</sup>	Natalizumab	International	III	Placebo	Efficacy/Safety	Yes, employees	Male	550/887	62.0%
Kappos et al., 2011 <sup>62</sup>	Ocrelizumab	International	II	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Female	141/218	64.7%
Hauser et al., 2017 (OPERA I) y OPERA II studies <sup>63</sup>	Ocrelizumab	International	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	1093/1656	66.0%
Montalban et al., 2017 (ORATORIO study) <sup>64</sup>	Ocrelizumab	International	III	Placebo	Efficacy/Safety	Yes, employees	Male	361/732	49.3%
Fox et al., 2018 <sup>65</sup>	Ocrelizumab	Post hoc analysis of ORATORIO study (Montalban et al., 2017)	III	Placebo	Efficacy	Yes, employees	Male	—	—
Wolinsky et al., 2018 <sup>66</sup>	Ocrelizumab	Post hoc analysis of ORATORIO study (Montalban et al., 2017)	III	Placebo	Efficacy	Yes, employees	Male	—	—
Barkhof et al., 2019 <sup>67</sup>	Ocrelizumab	Post hoc analysis of OPERA I and OPERA II studies (Hauser et al., 2017)	II/III	Interferon-beta-1a	Efficacy	Yes, employees	Male	—	—
Mayer et al., 2019 <sup>68</sup>	Ocrelizumab	Post hoc analysis of OPERA I and OPERA II studies (Hauser et al., 2017) and ORATORIO study (Montalban et al., 2017)	III	Placebo	Safety	Yes, employees	Female	—	—
Turner et al., 2019 <sup>69</sup>	Ocrelizumab	Post hoc analysis of OPERA I and OPERA II studies (Hauser et al., 2017)	III	Interferon-beta-1a	Efficacy/Safety	Yes, employees	Male	—	—
Hauser et al., 2008 <sup>70</sup>	Rituximab	International	II	Placebo	Efficacy/Safety	Yes, employees	Male	81/104	77.9%
Hawker et al., 2009 (OLYMPUS study) <sup>71</sup>	Rituximab	North America	II/III	Placebo	Efficacy/Safety	Yes, employees	Female	221/435	50.8%
Zhang et al., 2013 <sup>72</sup>	Rituximab	Post hoc of OLYMPUS study (Hawker et al., 2009)	II/III	Placebo	Efficacy	Yes, employees	Female	—	—
Honce et al., 2019 <sup>73</sup>	Rituximab	USA	II	Placebo	Efficacy	No	Male	37/53	69.8%

<sup>a</sup> Post hoc studies specified the original trial.<sup>b</sup> In multi arm EC, whenever one of them was an active drug, comparator was considered an active drug.<sup>c</sup> Only clinical trials were taken into account; the post hoc were not considered due to the fact that the population was the same.<sup>d</sup> PK/PD: Pharmacokinetic/pharmacodynamic assessment.

**Table 4** Proportion of women and other characteristics of gender allocation according to different subgroups.

Subgroup	Studies	Representation of women <sup>a</sup>			First female author (n/N)	Study design based on sex (n/N)	Analysis by sex		Results discussion by sex (n/N)	Pregnancy as exclusion criterion (n/N)	Recruitment
		No. patients	No. women	%			Principal variable analysis by sex (n/N)	15/55			
<b>Total</b>	<b>N</b>	<b>8815</b>	<b>5698</b>	<b>64.6</b>	<b>10/55</b>	<b>14/55</b>		<b>15/55</b>	<b>8/55</b>		<b>4/55</b>
<i>Type</i>											
CT	20	8815	5698	64.6	3/20	3/20		2/20	1/20		4/20
Post Hoc	35	<sup>a</sup>	<sup>a</sup>	<sup>a</sup>	7/35	11/35		13/35	7/35		0/35
<i>Investigational drug</i>											
Alentuzumab	14	1695	1111	65.6	1/14	2/14		3/14	2/14		0/14
Natalizumab	29	3922	2653	67.6	6/29	9/29		8/29	3/29		1/29
Ocrelizumab	8	2659	1595	61.4	1/8	2/8		2/8	2/8		0/8
Rituximab	4	592	339	57.3	2/4	1/4		2/4	1/4		3/4
<i>Geography</i>											
International	51	8221	5367	65.3	8/51	13/51		13/51	7/51		2/51
Other	4	594	331	55.7	2/4	1/4		2/4	1/4		2/4
<i>First female/male author</i>											
First female author	10	731	415	56.8	NA <sup>c</sup>	2/10		3/10	1/10		1/10
First male author	45	8084	5283	65.4	NA <sup>c</sup>	12/45		12/45	7/45		3/45
<i>Comparing factor</i>											
Placebo	25	3790	2272	59.9	6/25	6/25		6/25	3/25		4/25
Active drug <sup>b</sup>	30	5025	3426	68.2	4/30	8/30		9/30	5/30		0/30
<i>Date of publication</i>											
2000–2009	17	3567	2360	66.2	3/17	5/17		3/17	2/17		3/17
2010–2019	38	5248	3338	63.6	7/38	9/38		12/38	6/38		1/38
<i>Trial phase</i>											
Phase II	14	1318	815	61.8	1/14	1/14		3/14	1/14		3/14
Phase III	38	7262	4697	64.7	9/38	12/38		11/38	7/38		1/38
Phase IV	3	235	186	79.2	0/3	1/3		1/3	0/3		0/3
<i>Outcome</i>											
Efficacy	20	366	276	75.4	4/20	3/20		4/20	2/20		1/20
Safety	3	<sup>a</sup>	<sup>a</sup>	<sup>a</sup>	1/3	0/3		1/3	1/3		0/3
Efficacy and safety	30	8449	5422	64.2	4/30	10/30		8/30	4/30		3/30
PK/PD <sup>d</sup>	2	<sup>a</sup>	<sup>a</sup>	<sup>a</sup>	1/2	1/2		2/2	1/2		0/2
<i>Sample size</i>											
N 0–100	6	191	141	73.8	1/6	0/6		1/6	0/6		1/6
N 101–500	18	1875	1134	60.5	3/18	4/18		5/18	3/18		3/18
N 501–1000	14	3922	2468	62.9	2/14	5/14		4/14	2/14		0/14
N > 1000	17	2827	1955	69.2	4/17	5/17		5/17	3/17		0/17
<i>Funding</i>											
Pharmaceutical companies	48	8369	5476	65.4	10/48	13/48		13/48	7/48		3/48
Other	7	446	222	49.8	0/7	1/7		2/7	1/7		1/7

<sup>a</sup> Only clinical trials were taken into account, the post hoc trial were not included since the population was the same.<sup>b</sup> In multiarm trials, whenever one of them was active drug, the comparator was considered active drug.<sup>c</sup> NA = Non-applicable.<sup>d</sup> PK/PD = Pharmacokinetic/pharmacodynamic assessment.




Figure 1 Study selection flowchart.

Women represented 64.6% of all patients that were recruited in all CTs with a range of 18.3% to 85.0%. The first author of the publication was a woman in only 10 trials. The sex-separated analysis of the main variable was carried out in 15 out of the 55 included studies. Furthermore, only 8 CTs discussed the results based on gender. The exclusion of pregnant women is mentioned in only 4 of the 55 trials.

No trial meets any of the other 6 variables:

- analysis of the interaction between hormone replacement therapy and the active drug.
- inclusion of women using hormonal contraceptives.
- analysis of the interaction between hormonal contraceptives and the medication under study.
- analysis of the influence of the drug on the pharmacokinetics of hormonal contraceptives.
- analysis of the effects of the menstrual cycle phase on the pharmacodynamics of the drug.
- analysis of the influence of the phase of the menstrual cycle on the pharmacokinetics of the drug.

## Discussion

Our results show that, in the majority of the CTs of these four drugs, the percentage of women is higher than men. Contrary to what happens in similar reviews in other pathologies where women are often provided with insufficient or

inadequate representation. This could be justified by the higher prevalence of the disease in women than men and because the incidence of RRMS in women is increasing.<sup>7</sup> However, the ideal percentage of women in the trials should have been between 66% and 75% since the prevalence in women is usually 2 to 3 times higher than in men.

The data obtained is consistent, with a percentage of women of more than 50% in almost all studies. A progressive increase is observed in the phases of the CTs, with an inclusion of women of 61.83% in phase II and reaching almost 80% in phase IV. This issue could be related to the fact that previously, childbearing age women, never had to be admitted to phase I and II trials.<sup>75</sup> However, during the 1990s and thanks to the NIH-dependent Research Office on Women's Health (ORWH) and the FDA,<sup>74</sup> the previously mentioned prohibition was eliminated and the participation of women in all CTs was required; since the inclusion of women from the initial stages of drug development is essential for obtaining data on pharmacokinetic and pharmacodynamic differences according to gender; that lead the administration guideline in later phases.<sup>76</sup>

A lower gender bias is observed in studies funded by the pharmaceutical industry compared to independent studies. This could be explained because the development of monoclonal antibodies for MS is relatively recent and it seems that in the last few years there is a greater awareness of the pharmaceutical industry in following international recommendations that establish gender analysis as a minimum requirement of scientific validity to be able to extend the application of the results to the general patient population.<sup>15</sup>

The design of the study based on gender and analysis of the results arranged based on gender (main variable) is very rarely performed. The vast majority of the studies that analyze that design, are post hoc studies that come from original CT that do not take these variables into account. In fact, only one original CT discusses these results based on gender.<sup>71</sup> However, the influence of factors related to gender and type should be previously determined on the basis of their hypothetical role in the efficacy of the treatment. Authors should refrain from conducting a post hoc gender analysis if the study design is insufficient to allow meaningful conclusions.<sup>9</sup> Chilet et al. discuss the possibility that, in some trials, the analysis of the results arranged based on gender is performed, but this information is not finally published because, probably, the researchers do not find it relevant if no differences are found. However, knowing that there are no differences is also important.<sup>75</sup>

In two natalizumab CT where a sex-based analysis was performed, no significant differences were found in the efficacy of the natalizumab treatment between men and women.<sup>47,56</sup> However, in Hutchinson et al. trial, natalizumab showed a significant reduction in the progression of MS in women compared to the interferon beta 1.<sup>46</sup> In a clinical trial with 435 patients, it was determined that there are no differences in response to rituximab based on gender.<sup>71</sup> With regard to ocrelizumab, two clinical trials also reveal the same clinical benefit of the ocrelizumab treatment in women and men.<sup>66,69</sup> Finally, no significant differences were detected in the pharmacokinetics and pharmacodynamics of alemtuzumab according to gender,<sup>32</sup> however, those differences were detected in the prevalence of thyroid disorders in patients treated with alemtuzumab (higher in women, 29.7% vs. 15.8% of men).<sup>26</sup>

We found that only four of the trials indicate that pregnancy has been a reason for exclusion. It is likely that in the rest of the trials it was also a reason for exclusion, although it was not explicitly stated in the text of the article. In any case, it would have been important to express it so as not to raise doubts. Previous studies have shown that pregnancy has a strong influence on MS activity with a reduction in the frequency of relapses. During the third trimester the relapse rate is even 70% lower than before pregnancy. Post-partum, MS often worsens, with an increase in relapses 3–6 months after giving birth.<sup>3,4</sup> The improvement during pregnancy could be due to an increase in the proliferation of oligodendrocytes and in the number of myelinated axons in the maternal CNS, leading to greater remyelination.<sup>76</sup>

Furthermore, during pregnancy, sex hormones (estriol, progesterone, prolactin, and others) increase, producing an immunomodulatory and neuroprotective effect.<sup>76,77</sup>

Due to the lack of adequate and well-controlled studies of these four drugs in pregnant women, the FDA classifies all of them as category C, that is, the use during pregnancy should be avoided unless the potential benefit to the mother exceeds the potential risk to the fetus.<sup>78–81</sup>

As we have previously commented, no trial analyzes the interaction between hormonal contraceptives and the study drug. Because oral contraceptives contain estrogens (or estrogen receptor regulators) and progestogens, their influence on MS has been researched. Some studies suggest a positive effect of oral contraceptives, not only on symptoms but also on MRI activity and disease progression,

while others were associated with a slightly increased risk of multiple sclerosis and clinical syndrome isolated.<sup>3</sup>

The low number of women as first authors of these studies are also noteworthy. Giovanni et al. concluded,<sup>82</sup> that few women have reached the peak of academic neurology despite the availability of a considerable number of high-level academic neurologists and neuroscientists who have been successful worldwide. This could be due to the existence of gender bias in publication practices (editorial boards, scientific programs for professional meetings and recognition awards, etc.). However, it is curious that in studies where the first author is a woman, there is a lower representation of women and a greater gender bias.

The highlight of our work is that it is the first to study the gender differences of the biological drugs used in MS, considered one of the best options in certain types of MS, such as in PPMS, which continues to be developed to improve their efficacy tolerability and safety.

As the CT is the basic tool for evaluating the efficacy of drugs, the study population should be as real as possible. Therefore, women should be included in the study of drugs potentially used by them, the results should be shown sex-stratified results in the final drug approval reports and in the publication of CT, so that drug information can be obtained more personalized to promote a differential care for women and men if there is any difference in the efficacy or safety of the drugs between the two groups.

In the future, it would be desirable that the ethical committees do not allow the performance of CT which do not analyze gender in their design. Reviewers and editors of the journals also take this aspect into account as a requirement of scientific validity.

## Author disclosure statement

All authors have approved the final version for publication; they are responsible and can guarantee that all the aspects that make up the manuscript, have been reviewed and discussed among the authors so that they are exposed with the utmost precision and integrity.

## Funding statement

The present investigation has not received specific aid from agencies from the public sector, commercial sector or non-profit entities.

## Conflict of interests

The authors declare that they have no conflict of interest.

## References

- García Merino A, Ramón Ara Callizo J, Fernández Fernández O, Landete Pascual L, Moral Torres E, Rodríguez-AntigüedadZarrantz A. Consensus statement on the treatment

- of multiple sclerosis by the Spanish Society of Neurology in 2016. Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología. *Neurologia*. 2017;32:113–9, <http://dx.doi.org/10.1016/j.nrl.2016.02.026>.
2. Golden LC, Voskuhl R. The importance of studying sex differences in disease: the example of multiple sclerosis. *J Neurosci Res*. 2017;95(1–2):633–43, <http://dx.doi.org/10.1002/jnr.23955>.
  3. Ysraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. *Immunology*. 2019;156:9–22, <http://dx.doi.org/10.1111/imm.13004>.
  4. Airas L. Hormonal and gender-related immune changes in multiple sclerosis. *Acta Neurol Scand*. 2015;132:62–70, <http://dx.doi.org/10.1111/ane.12433>.
  5. Magyari M. Gender differences in multiple sclerosis epidemiology and treatment response. *Dan Med J*. 2016;63:B5212.
  6. Voge NV, Alvarez E. Monoclonal antibodies in multiple sclerosis: present and future. *Biomedicines*. 2019;7:20, <http://dx.doi.org/10.3390/biomedicines7010020>. Published 2019 Mar 14.
  7. Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS. Gender effects on treatment response to interferon-beta in multiple sclerosis. *Acta Neurol Scand*. 2014;130:374–9, <http://dx.doi.org/10.1111/ane.12277>.
  8. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research — amended; 2001. Available from: [http://grants.nih.gov/grants/funding/women\\_min/women\\_min.htm](http://grants.nih.gov/grants/funding/women_min/women_min.htm).
  9. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Equidad según sexo y de género en la investigación: justificación de las guías SAGER y recomendaciones para su uso [Sex and gender equity in research: rationale for the SAGER guidelines and recommended use]. *Gac Sanit*. 2019;33:203–10, <http://dx.doi.org/10.1016/j.gaceta.2018.04.003>.
  10. US Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice. *Fed Regist*. 1993;58:39409–16.
  11. ICH. Gender considerations in the conduct of clinical trials. (EMA/CHMP/3916/2005); 2020. Available from: <http://www.emea.europa.eu/pdfs/human/ich/391605en.pdf>. Accessed March 20, 2020.
  12. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals; 2014. Available from: [www.icmje.org/icmje-recommendations.pdf](http://www.icmje.org/icmje-recommendations.pdf).
  13. Canadian Institutes of Health Research. Gender, sex and health research guide: a tool for CIHR applicants; 2014. Available from: <http://www.cihr-irsc.gc.ca/e/32019.html>.
  14. Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. *J Acquir Immune Defic Syndr*. 2016;71:181–8, <http://dx.doi.org/10.1097/QAI.0000000000000842>.
  15. Santos-Casado M, García-Avello A. Systematic review of gender bias in the clinical trials of new long-acting antipsychotic drugs. *J Clin Psychopharmacol*. 2019;39:264–72, <http://dx.doi.org/10.1097/JCP.0000000000001041>.
  16. Jaggi R, Motomura AR, Amarnath S, Jankovic A, Sheets N, Ubel PA. Under-representation of women in high-impact published clinical cancer research. *Cancer*. 2009;115:3293–301, <http://dx.doi.org/10.1002/cncr.24366>.
  17. Phillips SP, Hamberg K. Doubly blind: a systematic review of gender in randomised controlled trials. *Glob Health Action*. 2016;9:29597, <http://dx.doi.org/10.3402/gha.v9.29597>. Published 2016 Apr 15.
  18. Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al., PRISMA-Equity Bellagio group. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. *PLoS Med*. 2012;9:e1001333, <http://dx.doi.org/10.1371/journal.pmed.1001333>.
  19. Coles AJ, Compston DA, Selman KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *N Engl J Med*. 2008;359:1786–801, <http://dx.doi.org/10.1056/NEJMoa0802670>.
  20. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selman KW, et al. Alemtuzumab versus interferon  $\beta$ -1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. *Lancet Neurol*. 2011;10:338–48, [http://dx.doi.org/10.1016/S1474-4422\(11\)70020-5](http://dx.doi.org/10.1016/S1474-4422(11)70020-5).
  21. Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. *Blood*. 2011;118:6299–305, <http://dx.doi.org/10.1182/blood-2011-08-371138>.
  22. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet*. 2012;380:1819–28, [http://dx.doi.org/10.1016/S0140-6736\(12\)61769-3](http://dx.doi.org/10.1016/S0140-6736(12)61769-3).
  23. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selman KW, et al. Alemtuzumab more effective than interferon  $\beta$ -1a at 5-year follow-up of CAMMS223 clinical trial. *Neurology*. 2012;78:1069–78, <http://dx.doi.org/10.1212/WNL.0b013e31824e8ee7>.
  24. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*. 2012;380:1829–39, [http://dx.doi.org/10.1016/S0140-6736\(12\)61768-1](http://dx.doi.org/10.1016/S0140-6736(12)61768-1).
  25. Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, et al. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. *Mult Scler*. 2013;19:1302–9, <http://dx.doi.org/10.1177/1352458513475722>.
  26. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. *J Clin Endocrinol Metab*. 2014;99:80–9, <http://dx.doi.org/10.1210/jc.2013-2201>.
  27. Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, et al. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon  $\beta$ -1a in MS. *Neurology*. 2016;87:1464–72, <http://dx.doi.org/10.1212/WNL.0000000000003169>.
  28. Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH, CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naïve relapsing-remitting multiple sclerosis patients. *J Neurol Sci*. 2016;363:188–94, <http://dx.doi.org/10.1016/j.jns.2016.02.025>.
  29. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selman KW, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology*. 2016;87:1985–92, <http://dx.doi.org/10.1212/WNL.0000000000003319>.
  30. Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. *Mult Scler*. 2017;23:67–1376, <http://dx.doi.org/10.1177/1352458516677589>.
  31. Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. *Neurology*. 2017;89:1107–16,

- <http://dx.doi.org/10.1212/WNL.0000000000004313>. Erratum in: *Neurology*. 2018;90:755.
32. Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. *Clin Exp Immunol*. 2018;194:295–314, <http://dx.doi.org/10.1111/cei.13208>.
  33. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2003;348:15–23, <http://dx.doi.org/10.1056/NEJMoa020696>.
  34. Dalton CM, Miskiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. *J Neurol*. 2004;251:407–13, <http://dx.doi.org/10.1007/s00415-004-0332-4>.
  35. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. *Neurology*. 2004;62:2038–43, <http://dx.doi.org/10.1212/01.wnl.0000128136.79044.d6>.
  36. O'Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, et al. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. *Mult Scler*. 2005;11:568–72, <http://dx.doi.org/10.1191/1352458505ms1205oa>.
  37. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2006;354:899–910, <http://dx.doi.org/10.1056/NEJMoa044397>.
  38. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med*. 2006;354:911–23, <http://dx.doi.org/10.1056/NEJMoa044396>.
  39. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. *Neurology*. 2007;68:1299–304, <http://dx.doi.org/10.1212/01.wnl.0000259521.14704.a8>.
  40. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. *Neurology*. 2007;69:1391–403, <http://dx.doi.org/10.1212/01.wnl.0000277457.17420.b5>.
  41. Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, et al. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. *J Neurol*. 2007;254:306–14, <http://dx.doi.org/10.1007/s00415-006-0356-z>.
  42. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. *Neurology*. 2007;68:1390–401, <http://dx.doi.org/10.1212/01.wnl.0000260064.77700.fd>.
  43. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. *Ann Neurol*. 2007;62:335–46, <http://dx.doi.org/10.1002/ana.21163>.
  44. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. *Neurology*. 2009;72:806–12, <http://dx.doi.org/10.1212/01.wnl.0000343880.13764.69>. PMID: 19255407.
  45. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. *Lancet Neurol*. 2009;8:254–60, [http://dx.doi.org/10.1016/S1474-4422\(09\)70021-3](http://dx.doi.org/10.1016/S1474-4422(09)70021-3).
  46. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. *J Neurol*. 2009;256:405–15, <http://dx.doi.org/10.1007/s00415-009-0093-1>. Erratum in: *J Neurol*. 2009;256:1035–7.
  47. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci*. 2010;292:28–35, <http://dx.doi.org/10.1016/j.jns.2010.02.012>.
  48. Bates D, Bartholomé E. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. *J Neurol Neurosurg Psychiatry*. 2012;83:55–60, <http://dx.doi.org/10.1136/jnnp-2011-300279>.
  49. Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. *Arch Neurol*. 2011;68:464–8, <http://dx.doi.org/10.1001/archneurol.2011.45>.
  50. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. *Mult Scler*. 2011;17:970–9, <http://dx.doi.org/10.1177/1352458511399611>.
  51. Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. *J Neurol Sci*. 2012;318:119–24, <http://dx.doi.org/10.1016/j.jns.2012.03.009>.
  52. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. *J Neurol*. 2012;259:898–905, <http://dx.doi.org/10.1007/s00415-011-6275-7>.
  53. Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. *J Neurol*. 2013;260:1388–95, <http://dx.doi.org/10.1007/s00415-012-6809-7>.
  54. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. *Neurology*. 2014;82:1491–8, <http://dx.doi.org/10.1212/WNL.0000000000000355>. Erratum in: *Neurology*. 2015;84:862.
  55. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. *J Neurol Sci*. 2014;341(1–2):22–7, <http://dx.doi.org/10.1016/j.jns.2014.03.035>.
  56. Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. *Mult Scler Relat Disord*. 2014;3:705–11, <http://dx.doi.org/10.1016/j.msard.2014.08.005>.
  57. Chahin S, Balcer LJ, Miller DM, Zhang A, Galetta SL. Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life. *J Neuroophthalmol*. 2015;35:6–11, <http://dx.doi.org/10.1097/WNO.0000000000000173>.
  58. Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. *J Neurol*. 2015;262:326–36, <http://dx.doi.org/10.1007/s00415-014-7558-6>.

59. Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. *Neurology*. 2017;89:1584–93, <http://dx.doi.org/10.1212/WNL.0000000000004485>. Erratum in: *Neurology*. 2020;95:661.
60. Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. *Mult Scler Relat Disord*. 2017;11:25–31, <http://dx.doi.org/10.1016/j.msard.2016.11.002>.
61. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurol*. 2018;17:405–15, [http://dx.doi.org/10.1016/S1474-4422\(18\)30069-3](http://dx.doi.org/10.1016/S1474-4422(18)30069-3).
62. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet*. 2011;378:1779–87, [http://dx.doi.org/10.1016/S0140-6736\(11\)61649-8](http://dx.doi.org/10.1016/S0140-6736(11)61649-8).
63. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med*. 2017;376:221–34, <http://dx.doi.org/10.1056/NEJMoa1601277>.
64. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med*. 2017;376:209–20, <http://dx.doi.org/10.1056/NEJMoa1606468>.
65. Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, et al. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. *Mult Scler*. 2018;24:1862–70, <http://dx.doi.org/10.1177/1352458518808189>.
66. Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. *Ann Neurol*. 2018;84:527–36, <http://dx.doi.org/10.1002/ana.25313>.
67. Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. *Neurology*. 2019;93:e1778–86, <http://dx.doi.org/10.1212/WNL.0000000000008189>.
68. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
69. Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. *J Neurol*. 2019;266:1182–93, <http://dx.doi.org/10.1007/s00415-019-09248-6>.
70. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med*. 2008;358:676–88, <http://dx.doi.org/10.1056/NEJMoa0706383>.
71. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. *Ann Neurol*. 2009;66:460–71, <http://dx.doi.org/10.1002/ana.21867>.
72. Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. *Mult Scler*. 2013;19:775–81, <http://dx.doi.org/10.1177/1352458512459685>.
73. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. *Neurology*. 2019;92:e723–32, <http://dx.doi.org/10.1212/WNL.0000000000006916>.
74. Arenere Mendoza M, Cilveti-Sanchez U, Idopie Tomas A, Izuel-Rami M, Navarro Aznarez H, Palomo Palomo P. Influencia del género en investigación clínica. *Farm Hosp*. 2004;28:440–4.
75. Chilet Rosell E, Ruiz Cantero MT, Laguna-Goya N, De Andres Rodriguez-Trelles F. Recommendations for the study and evaluation of gender differences in clinical trials in Spain]. *Med Clin (Barc)*. 2010;135:130–4.
76. Avila M, Bansal A, Culberson J, Peiris AN. The role of sex hormones in multiple sclerosis. *Eur Neurol*. 2018;80:93e9.
77. Bilbao MM, Durán SB, Llona JB, Rodríguez-Antigüedad A. Esclerosis múltiple, maternidad y cuestiones relacionadas con el género. *Neurología*. 2019;34:259–69.
78. Product Information of ocrelizumab. FDA: Food and drug Administration [Internet]. U.S.; 2017 Mar; [cited 2019 Feb 18]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/761053lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf).
79. Product Information of natalizumab. FDA: Food and drug Administration [Internet]. U.S.; 2017 Mar; [cited 2019 Feb 18]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/125104s106lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125104s106lbl.pdf).
80. Product Information of rituximab. FDA: Food and drug Administration [Internet]. U.S.; 2017 Mar; [cited 2019 Feb 18]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/103705s5367s5388lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf).
81. Product Information of alemtuzumab. FDA: Food and drug Administration [Internet]. U.S.; 2017 Mar; [cited 2019 Feb 18]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/103948s5163s5164s1bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103948s5163s5164s1bl.pdf).
82. Giovannoni G. Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS? *Mult Scler Relat Disord*. 2019;28:153–4.